AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27930500 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (up to 6 mg/d)
Number of subjects: 36
Study 27930500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 27930500 — intervention group
Group type: COMPARATOR
Intervention: Prior treatment regimen (SSRIs plus sodium valproate)
Number of subjects: 36
Study 25911899 — intervention group
Group type: EXPERIMENTAL
Intervention: rebamipide 300 mg daily for 8 weeks plus rabeprazole 20 mg daily for the first 4 weeks (reb+PPI group)
Number of subjects: 0
Study 25911899 — intervention group
Group type: COMPARATOR
Intervention: rabeprazole 20 mg daily for 8 weeks (PPI group)
Number of subjects: 0
Study 24703195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 25 mg qd
Number of subjects: 2736
Study 24703195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg qd
Number of subjects: 2736
Study 24703195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg qd
Number of subjects: 2736
Study 24703195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2736
Study 24703195 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg
Number of subjects: 2736
Study 25191556 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ) 500 ml
Number of subjects: 28
Study 25191556 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink 500 ml
Number of subjects: 28
Study 18972429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial (IA) chemoradiation
Number of subjects: 207
Study 18972429 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) chemoradiation
Number of subjects: 207
Study 18972429 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IA and IV groups
Number of subjects: 207
Study 17892539 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterally wedged insoles
Number of subjects: 200
Study 17892539 — intervention group
Group type: COMPARATOR
Intervention: Control flat insoles
Number of subjects: 200
Study 15976208 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine-neostigmine
Number of subjects: 80
Study 15976208 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine-midazolam
Number of subjects: 80
Study 15976208 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine-ketamine
Number of subjects: 80
Study 15976208 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine alone
Number of subjects: 80
Study 12069211 — intervention group
Group type: COMPARATOR
Intervention: Steady-state group (24 outpatients)
Number of subjects: 47
Study 12069211 — intervention group
Group type: EXPERIMENTAL
Intervention: VOC group (14 inpatients during crisis)
Number of subjects: 47
Study 12069211 — intervention group
Group type: COMPARATOR
Intervention: Steady-state and VOC groups
Number of subjects: 47
Study 9489264 — intervention group
Group type: EXPERIMENTAL
Intervention: Task Force's selection of criteria for identifying effective treatments
Number of subjects: 0
Study 9489264 — intervention group
Group type: COMPARATOR
Intervention: Less stringent and controlled research designs
Number of subjects: 0
Study 7616875 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of progesterone
Number of subjects: 0
Study 7616875 — intervention group
Group type: COMPARATOR
Intervention: Vaginal administration of progesterone
Number of subjects: 0
Study 1754870 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0
Study 1754870 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 0
Study 1754870 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0
Study 6820344 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (360 mg/die)
Number of subjects: 47
Study 6820344 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/die)
Number of subjects: 47
Study 6820344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31819995 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept plus MTX
Number of subjects: 881
Study 31819995 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 881
Study 30900392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 3.0 mg/kg (up to 150 mg)
Number of subjects: 234
Study 30900392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 1.2 mg/kg (up to 60 mg)
Number of subjects: 234
Study 30900392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 0.4 mg/kg (up to 20 mg)
Number of subjects: 234
Study 30900392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 5.0 mg/kg (up to 150 mg) in subjects under 12 years
Number of subjects: 234
Study 30900392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 29453466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal Dexmedetomidine (5 micrograms)
Number of subjects: 76
Study 29453466 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric Bupivacaine 0.5% (2.5 ml)
Number of subjects: 76
Study 27553824 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Number of subjects: 0
Study 24046462 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 17
Study 24046462 — intervention group
Group type: COMPARATOR
Intervention: Non-rebreathing mask
Number of subjects: 17
Study 22490626 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan + Amlodipine
Number of subjects: 61
Study 22490626 — intervention group
Group type: COMPARATOR
Intervention: Valsartan + Hydrochlorothiazide
Number of subjects: 61
Study 20073301 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional discectomy (group A, 25 cases)
Number of subjects: 65
Study 20073301 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior lumbar interbody fusion (PLIF) (group B, 22 cases)
Number of subjects: 65
Study 20073301 — intervention group
Group type: COMPARATOR
Intervention: Transforaminal lumbar interbody fusion (TLIF) (group C, 18 cases)
Number of subjects: 65
Study 20073301 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior lumbar interbody fusion (PLIF) (group B)
Number of subjects: 65
Study 20073301 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional discectomy (group A)
Number of subjects: 65
Study 20073301 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal lumbar interbody fusion (TLIF) (group C)
Number of subjects: 65
Study 20073301 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 65
Study 20073301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervertebral space height (ISH)
Number of subjects: 65
Study 17233426 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (shorter-acting) for adjustment disorder
Number of subjects: 0
Study 17233426 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants for major depression
Number of subjects: 0
Study 17233426 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptics (haloperidol) for delirium
Number of subjects: 0
Study 15037867 — intervention group
Group type: EXPERIMENTAL
Intervention: His452Tyr genotype
Number of subjects: 27
Study 15037867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine response
Number of subjects: 27
Study 15037867 — intervention group
Group type: EXPERIMENTAL
Intervention: T102C genotype
Number of subjects: 27
Study 15037867 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 12577248 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous amifostine 500 mg before each radiation therapy fraction
Number of subjects: 41
Study 12577248 — intervention group
Group type: COMPARATOR
Intervention: No amifostine (control group)
Number of subjects: 41
Study 12577248 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous amifostine
Number of subjects: 41
Study 9881038 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening programs for early diagnosis of colorectal cancer
Number of subjects: 0
Study 8567765 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH (Puregon)
Number of subjects: 981
Study 8567765 — intervention group
Group type: COMPARATOR
Intervention: Urinary FSH (Metrodin)
Number of subjects: 981
Study 2665492 — intervention group
Group type: EXPERIMENTAL
Intervention: 365 mg of elemental magnesium daily (as magnesium aspartate hydrochloride)
Number of subjects: 374
Study 2665492 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 374
Study 343024 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with adriamycin
Number of subjects: 117
Study 343024 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy without adriamycin
Number of subjects: 117
Study 31653260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (attended twice weekly exercise and nutrition classes for 24 weeks)
Number of subjects: 0
Study 31653260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (self-reported physical activity)
Number of subjects: 0
Study 31653260 — intervention group
Group type: COMPARATOR
Intervention: Control group (attended didactic healthy lifestyle classes monthly)
Number of subjects: 0
Study 28575761 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800mg QD
Number of subjects: 1447
Study 28575761 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1200mg QD
Number of subjects: 1447
Study 28575761 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 400mg QD
Number of subjects: 1447
Study 28575761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1447
Study 26466310 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid PTSD and major depressive disorder (MDD)
Number of subjects: 158
Study 26466310 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD numbing symptoms
Number of subjects: 158
Study 26466310 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 158
Study 26466310 — intervention group
Group type: COMPARATOR
Intervention: PTSD alone
Number of subjects: 158
Study 22543515 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit
Number of subjects: 30
Study 22543515 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 30
Study 21131392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot drilling with a diameter of 1.1 mm (Group I)
Number of subjects: 62
Study 21131392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot drilling with a diameter of 0.9 mm (Group II)
Number of subjects: 62
Study 21131392 — intervention group
Group type: COMPARATOR
Intervention: Drill-free method (Group III)
Number of subjects: 62
Study 19715461 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in hospital rooms with live plants during postoperative recovery periods
Number of subjects: 90
Study 19715461 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients in similar rooms without plants)
Number of subjects: 90
Study 17916223 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum + motivational interviewing counseling
Number of subjects: 755
Study 17916223 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum + Health Education counseling
Number of subjects: 755
Study 17916223 — intervention group
Group type: COMPARATOR
Intervention: Placebo + motivational interviewing counseling
Number of subjects: 755
Study 17916223 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Health Education counseling
Number of subjects: 755
Study 15289215 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy (medical therapy and coronary angiography at 4 to 48 hours)
Number of subjects: 2220
Study 15289215 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (medical therapy and predischarge exercise testing)
Number of subjects: 2220
Study 15289215 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 2220
Study 11450767 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited macular translocation (LMT)
Number of subjects: 0
Study 11450767 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy
Number of subjects: 0
Study 11450767 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 9371851 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) measuring brain activity in dyslexic subjects
Number of subjects: 0
Study 9371851 — intervention group
Group type: COMPARATOR
Intervention: Functional magnetic resonance imaging (fMRI) measuring brain activity in control subjects
Number of subjects: 0
Study 9371851 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of reading rate and brain activity
Number of subjects: 0
Study 7951640 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 0
Study 3310628 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g suspension four times daily for eight weeks)
Number of subjects: 49
Study 3310628 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg film-coated tablet twice daily for eight weeks)
Number of subjects: 49
Study 3310628 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 49
Study 3310628 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 49
Study 3310628 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 49
Study 28645542 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of ingroup member who challenged the group's norm in moral contexts
Number of subjects: 73
Study 28645542 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of outgroup member who supported the group's norm in social-conventional contexts
Number of subjects: 73
Study 28645542 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related differences in inclusion decisions
Number of subjects: 73
Study 28645542 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning about inclusion decisions
Number of subjects: 73
Study 26280662 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant-essential oil gel applied twice daily after brushing
Number of subjects: 30
Study 26280662 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo gel)
Number of subjects: 30
Study 24962527 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndesmotic screw fixation
Number of subjects: 140
Study 24962527 — intervention group
Group type: COMPARATOR
Intervention: No syndesmotic fixation
Number of subjects: 140
Study 23498303 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle weight-loss intervention (7% weight loss goal achieved and maintained by caloric restriction and increased physical activity)
Number of subjects: 301
Study 23498303 — intervention group
Group type: COMPARATOR
Intervention: Usual care (two visits with a registered dietitian and monthly newsletters)
Number of subjects: 301
Study 23498303 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 301
Study 23498303 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle weight-loss intervention
Number of subjects: 301
Study 21624216 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 63
Study 21624216 — intervention group
Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 63
Study 18165968 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0
Study 18165968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17056953 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided sedation
Number of subjects: 100
Study 17056953 — intervention group
Group type: EXPERIMENTAL
Intervention: AAI-guided sedation
Number of subjects: 100
Study 17056953 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS/AAI-guided sedation
Number of subjects: 100
Study 17056953 — intervention group
Group type: COMPARATOR
Intervention: Clinically guided sedation
Number of subjects: 100
Study 14583134 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol/2.0% MK-507 combination b.i.d.
Number of subjects: 20
Study 14583134 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol b.i.d. and 2.0% MK-507 b.i.d. (concomitant treatment)
Number of subjects: 20
Study 14583134 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 20
Study 10760103 — intervention group
Group type: EXPERIMENTAL
Intervention: SB 290670 (mixed endothelin A and B receptor antagonist)
Number of subjects: 158
Study 10760103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 10760103 — intervention group
Group type: EXPERIMENTAL
Intervention: SB 290670
Number of subjects: 158
Study 8813984 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (1200 mg) via TVA-Bier
Number of subjects: 32
Study 8813984 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (284 mg) via TVA-Bier
Number of subjects: 32
Study 8813984 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (1200 mg) via intravenous/intra-arterial injection
Number of subjects: 32
Study 8813984 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin (284 mg) via intravenous/intra-arterial injection
Number of subjects: 32
Study 1445966 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.25 micrograms/kg IV
Number of subjects: 7
Study 1445966 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.5 micrograms/kg IV
Number of subjects: 7
Study 1445966 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1 microgram/kg IV
Number of subjects: 7
Study 1445966 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms/kg IV
Number of subjects: 7
Study 1445966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 4015079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal HuIFN‐alpha 2 (1.25 X 10(6) IU)
Number of subjects: 287
Study 4015079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 30765294 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragility Index (FI)
Number of subjects: 206
Study 30765294 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragility Index (FI) in ischemic stroke RCTs
Number of subjects: 206
Study 29630755 — intervention group
Group type: EXPERIMENTAL
Intervention: FraGW (automated breast density measure)
Number of subjects: 50
Study 29630755 — intervention group
Group type: EXPERIMENTAL
Intervention: Fra80 (previous breast density measurement)
Number of subjects: 50
Study 29630755 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD (converted from FraGW)
Number of subjects: 50
Study 26658173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (hydrocortisone)
Number of subjects: 0
Study 26658173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26658173 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 0
Study 24182419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (50 mg) plus promethazine (25 mg)
Number of subjects: 242
Study 24182419 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan (50 mg) plus placebo
Number of subjects: 242
Study 22825231 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention (training to implement AAR, workflow integration recommendations, tobacco cessation poster, support visit)
Number of subjects: 16
Study 20414672 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forced oscillation pressure wave on spontaneous respiration
Number of subjects: 10
Study 18584220 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% or 3% N-chlorotaurine (NCT) mouth rinse
Number of subjects: 80
Study 18584220 — intervention group
Group type: EXPERIMENTAL
Intervention: N-chlorotaurine (NCT) mouth rinse
Number of subjects: 80
Study 18584220 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 80
Study 18584220 — intervention group
Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 80
Study 16082267 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg d‐amphetamine (Treatment group, N = 4)
Number of subjects: 8
Study 16082267 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Placebo group, N = 4)
Number of subjects: 8
Study 11507929 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.0% sodium hexametaphosphate dentifrice
Number of subjects: 159
Study 11507929 — intervention group
Group type: COMPARATOR
Intervention: 5.0% ionic pyrophosphate dentifrice (control)
Number of subjects: 159
Study 10433160 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid dialysis
Number of subjects: 7
Study 10433160 — intervention group
Group type: COMPARATOR
Intervention: Dextrose dialysis
Number of subjects: 7
Study 7586936 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOC‐201
Number of subjects: 6
Study 7586936 — intervention group
Group type: COMPARATOR
Intervention: Autologous transfusion
Number of subjects: 6
Study 2319000 — intervention group
Group type: EXPERIMENTAL
Intervention: FEP smooth surface
Number of subjects: 16
Study 2319000 — intervention group
Group type: COMPARATOR
Intervention: CA smooth surface
Number of subjects: 16
Study 2319000 — intervention group
Group type: EXPERIMENTAL
Intervention: FEP rough surface
Number of subjects: 16
Study 2319000 — intervention group
Group type: COMPARATOR
Intervention: CA rough surface
Number of subjects: 16
Study 31955699 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 65
Study 31523057 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians viewing clinical vignettes alongside PREDICT Prostate estimates
Number of subjects: 190
Study 31523057 — intervention group
Group type: COMPARATOR
Intervention: Clinicians viewing clinical vignettes with clinical information alone
Number of subjects: 190
Study 28150384 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care program
Number of subjects: 236
Study 28150384 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 236
Study 26062731 — intervention group
Group type: EXPERIMENTAL
Intervention: G-I (one session treatment of autologous haematopoietic stem cells)
Number of subjects: 90
Study 26062731 — intervention group
Group type: EXPERIMENTAL
Intervention: G-II (two sessions treatment of autologous haematopoietic stem cells)
Number of subjects: 90